exelixis stock: Company & Market Guide

A comprehensive, beginner-friendly guide to exelixis stock (EXEL) covering company background, stock identifiers, market performance, financials, pipeline drivers, risks, analyst coverage, filings ...

2024-07-10 00:49:00

By Crypto Trailblazer

Article rating

4.6

107 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Exelixis, Inc. (EXEL)

exelixis stock is the common equity of Exelixis, Inc., a U.S.-based oncology biotechnology company focused on discovering, developing, and commercializing small-molecule therapies for cancer. This guide explains what exelixis stock represents, how the company generates revenue, trading identifiers and hours, historical price context, key financial metrics, pipeline catalysts, risks, analyst coverage, and where to find official filings and quotes. Readers will gain a practical overview suitable for investors and researchers who want to understand the profile and market behavior of exelixis stock.

As of 2026-01-27, according to Exelixis Investor Relations and major financial data providers, the overview and metrics below summarize the most relevant public information for exelixis stock and its market presence.

Company background

Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. The company’s mission centers on advancing novel oncology therapies by combining discovery research, clinical development, and commercialization. Over more than two decades, Exelixis established itself as a commercial-stage oncology biotech company with a focus on kinase inhibitors and targeted small molecules.

Major marketed products that have historically driven revenue for Exelixis include cabozantinib-based therapies. Cabozantinib is marketed in multiple formulations and indications under brand names that have been central to Exelixis’s commercial profile. Revenue from cabozantinib formulations—used in renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and other indications—constitutes a large portion of the company’s commercial sales. Exelixis has also pursued combination regimens and label expansions through ongoing clinical programs.

Exelixis’s strategy combines maximizing the commercial opportunity for its marketed medicines while advancing a pipeline of investigational candidates, often in combination with partners and collaborators. The company’s investor relations pages and annual reports document its historical milestones, regulatory approvals, and strategic partnerships.

Stock overview

Ticker symbol: EXEL (common stock)
Exchange: NASDAQ Global Select Market
ISIN: (refer to Exelixis Investor Relations for the exact ISIN associated with EXEL)
Sector / industry: Healthcare — Biotechnology / Pharmaceuticals
IPO / listing: Exelixis completed its public listing in the mid-2000s; for the definitive IPO/listing date consult the company’s SEC filings and IR timeline.

Trading notes:

NASDAQ regular trading hours generally run from 09:30 to 16:00 Eastern Time on U.S. business days; pre-market and after-hours sessions also exist with lower liquidity.
Real-time quotes may be subject to short delays on some public websites; many professional terminals display real-time data. Retail quote pages typically indicate whether a quote is delayed (e.g., 15-20 minutes) — confirm the timestamp on any quote before acting.

As of 2026-01-27, according to NASDAQ and Exelixis Investor Relations, investors and market participants track exelixis stock using the EXEL ticker during these trading windows and check official filings for corporate action notices.

Market capitalization and float

Market capitalization and float are dynamic metrics that reflect investor valuation and available shares for public trading. As of 2026-01-27, major public financial portals report exelixis stock market capitalization in the multi-billion-dollar range; investors should consult live quotes for an exact figure.

Important considerations for market-cap and float in the context of exelixis stock:

Market capitalization reflects the market value of all outstanding common shares and can move materially with share price changes driven by clinical data, earnings, or sector rotations.
Float (shares available for public trading) can be affected by insider holdings, institutional ownership, and lock-up or restricted shares. A smaller free float can increase price volatility for biotech names like exelixis stock when event-driven flows occur.
Institutional ownership concentration matters: high institutional ownership can support liquidity but may also mean concentrated selling if funds rebalance.

Investors seeking precise numbers (market cap, shares outstanding, and float) should reference Exelixis’s most recent 10-Q/10-K and reputable market-data providers for up-to-date, verifiable values.

Trading characteristics

Typical trading characteristics for exelixis stock include:

Average daily volume: exelixis stock typically trades in the millions of shares per day on average, reflecting meaningful retail and institutional interest for a mid-to-large biotech name. As of 2026-01-27, major quote providers report average daily volume figures that help gauge liquidity for order execution.
Beta (volatility vs. the broader market): Biotech equities often display betas above 1.0, indicating higher volatility relative to the broad market. exelixis stock historically demonstrates elevated short-term volatility around binary clinical events and earnings announcements.
Trading currency: U.S. dollars (USD).
Investor profile: exelixis stock is commonly held by healthcare- and biotech-focused institutional investors, mutual funds, and individual investors seeking exposure to oncology development and commercial revenue streams. Given its commercial product base, EXEL often sits between early-stage biotech plays and larger commercial pharmaceutical equities in investor portfolios.

For precise, current values of average daily volume and beta, consult real-time market-data providers and the company’s IR disclosures.

Historical price performance

Historical price performance provides context for exelixis stock’s past volatility and long-term trends. Key price metrics typically referenced by investors include:

52-week high and low: these figures summarize the one-year trading range for exelixis stock and are commonly listed on financial-data pages.
Multi-year performance: investors review 1-, 3-, and 5-year total-return charts that include dividends (if any) and share-price change to understand longer-term trends.
Notable price milestones: such as post-approval run-ups, post-earnings reactions, and responses to major clinical data releases.

As of 2026-01-27, according to major financial portals and Exelixis IR historical price resources, exelixis stock has experienced periods of sharp upside on favorable clinical or commercial news and material pullbacks following disappointing trial outcomes or broader sector weakness. For exact historical highs, lows, and percentage returns over specified intervals, consult the company’s historical price lookup on its IR site or data platforms that provide downloadable price histories.

Financial profile

Investors use several high-level financial metrics to assess a company like Exelixis and its exelixis stock. Key items include:

Revenue: Exelixis’s revenue is primarily driven by commercial sales of cabozantinib formulations and potentially partnerships or milestone receipts. Recent annual and quarterly revenue figures are published in the company’s 10-Q/10-K and earnings releases.
Net income / loss and EPS (TTM): Exelixis’s profitability profile has varied over time as the company balanced commercial expansion, R&D spending, and potential one-time items. EPS (trailing twelve months) and adjusted non-GAAP results are commonly reported in earnings materials.
Valuation metrics: P/E ratio (trailing and forward) may be presented on a trailing-earnings basis when the company is profitable; for companies with negative trailing net income, forward P/E or EV/Revenue multiples and enterprise-value measures are used instead.
Margins: Gross margin is influenced by product mix and cost of goods sold; operating and net margins reflect R&D and SG&A spending.

As of 2026-01-27, investors should refer to Exelixis’s latest quarterly earnings release and SEC filings for the most recent revenue, EPS (TTM), and margin data. Public data portals also summarize trailing twelve-month metrics and common valuation multiples used by analysts to compare exelixis stock with peers.

Note: This guide refrains from making forward-looking statements about future financial performance and instead points readers to primary reports for verified figures.

Business drivers and product pipeline

Commercial drivers

Cabozantinib formulations remain the primary commercial revenue driver for Exelixis. Indications such as renal cell carcinoma and hepatocellular carcinoma historically provided the foundation for product sales. Label expansions, new formulation rollouts, and market penetration strategies directly influence revenue trends and investor sentiment for exelixis stock.

Pipeline and investigational assets

Exelixis maintains a clinical pipeline of investigational candidates and combination studies centered around oncology indications. Lead assets and their progress through Phase 1–3 trials are major valuation drivers for exelixis stock because positive trial readouts can materially re-rate biotech shares.

Collaborations and partnerships

Strategic collaborations, co-development deals, and licensing agreements can provide milestone payments, shared development costs, and broadened commercialization pathways. Announcements of new partnerships or expanded collaborations often influence investor perception of exelixis stock’s potential upside and de-risking.

Impact on valuation

For exelixis stock, the balance between recurring commercial revenue from approved products and binary pipeline events (trial readouts, regulatory approvals) shapes both near-term volatility and medium-term valuation prospects. Pipeline successes can create significant upside, while clinical or regulatory setbacks typically exert downward pressure.

As of 2026-01-27, Exelixis’s active clinical programs and any recently reported readouts are listed in investor materials and press releases; these items are routinely referenced by analysts when updating exelixis stock models.

Recent corporate events and material developments

Material corporate events that commonly affect exelixis stock include quarterly earnings releases with guidance updates, major clinical trial readouts, partnership announcements, and capital allocation decisions such as share repurchases or secondary offerings.

Earnings and guidance: Quarterly results and management commentary on revenue, margin trends, and guidance materially influence short-term trading in exelixis stock. Investors often watch for changes in revenue guidance tied to product uptake.
Clinical readouts: Phase 2/3 efficacy and safety results for cabozantinib combinations or other pipeline agents are binary events that can cause significant price movement in exelixis stock.
Corporate actions: Announced share repurchase programs, large insider transactions, or changes to the board can alter supply/demand dynamics for exelixis stock.

As of 2026-01-27, recent corporate announcements, earnings releases, and trial updates are documented in Exelixis press releases and SEC filings. Investors should note the reported dates and details of these events directly from company disclosures. For instance, “As of 2026-01-27, according to Exelixis Investor Relations, the company reported its most recent quarterly results and updated guidance on [date of release]” — consult the IR press release archive for the exact release date and numeric details.

Analyst coverage and market consensus

Analyst coverage influences short- and medium-term expectations for exelixis stock. Elements to monitor include:

Rating distribution: Analysts typically classify recommendations as Buy/Outperform, Hold/Neutral, or Sell/Underperform. The mix across coverage sets a consensus sentiment.
Price targets: Changes in analyst price targets following trial results or earnings can prompt re-evaluation of exelixis stock.
Earnings estimates and model updates: Analysts publish updated revenue and EPS forecasts after quarterly results or material news that affects the company’s commercial outlook.

As of 2026-01-27, major financial services and sell-side analysts cover Exelixis, and their aggregated recommendations and target prices are summarized on public financial portals. Readers should consult analyst reports and the company’s IR for a full listing of coverage and the dates of recent updates.

Note: Analyst views are one input among many and do not constitute investment advice.

Ownership and insider transactions

Understanding who owns exelixis stock helps evaluate ownership concentration and potential supply-side risks.

Institutional ownership: A sizable portion of exelixis stock is commonly held by institutional investors, healthcare-focused funds, and index/ETF holders that include biotech exposure. High institutional ownership can support liquidity but may also lead to correlated selling during sector rotations.
Insider transactions: Director and executive trades (purchases or sales) are reported under SEC Section 16 filings and can signal management views; however, sales by insiders are frequently for personal liquidity and do not necessarily reflect negative company outlooks.

As of 2026-01-27, public filings and aggregated ownership summaries available through the company’s investor relations and regulatory disclosures list institutions with significant holdings and any recent Section 16 filings. Investors should review the filing dates to verify the timing and size of insider transactions and institutional disclosures.

Risks and investment considerations

Investors interested in exelixis stock should weigh standard biotechnology sector risks alongside company-specific considerations:

Clinical and regulatory risk: Trial failures, safety signals, or regulatory delays for investigational assets can lead to large negative share-price moves. Because Exelixis operates in oncology, binary trial outcomes can be particularly consequential.
Commercial risk and competition: Competing therapies, pricing pressures, and payer dynamics can affect uptake and revenue for cabozantinib formulations. Patent expirations, biosimilars, or alternative therapeutic classes are additional commercial risks.
Concentration and pipeline dependency: Companies concentrated around a small number of marketed products or a few late-stage programs can exhibit greater sensitivity to single-event outcomes.
Market and liquidity risk: Biotech stocks are often more volatile than broader indices. Market-wide sell-offs, sector rotation, or declines in risk appetite can disproportionately affect exelixis stock.
Execution risk: Manufacturing, supply chain, and commercialization execution issues can impact revenue and margins.

This guide remains neutral and factual; it does not offer investment recommendations. Investors should consult the company’s risk disclosures in its 10-K and 10-Q filings for a comprehensive risk list and assess their own risk tolerance before making any decisions.

Trading and technical analysis resources

Market participants use a combination of fundamental and technical tools to analyze exelixis stock. Common technical and trading resources include:

Charting platforms: Interactive charting services provide intraday and multi-year charts with overlays such as moving averages (50-day, 200-day), Relative Strength Index (RSI), MACD, and volume profiles that traders use to identify momentum and support/resistance.
Option market activity: Option open interest, put/call ratios, and unusual options volumes can indicate hedging, speculation, or expectations around upcoming events for exelixis stock.
Intraday liquidity and order-book depth: For active traders, real-time level-2 data and time-and-sales feeds help assess execution risk for larger orders.

For practical use, investors and traders may monitor intraday charts ahead of earnings or trial readouts and track longer-term technical themes (e.g., trendlines, breakouts) to align risk management. Bitget’s trading platform offers charting and option instruments where available; consider the platform’s tools for order types, stop-loss functionality, and risk controls when trading.

Historical filings and investor relations resources

Where to find authoritative filings and materials for exelixis stock:

SEC filings: The company’s 10-K (annual report), 10-Q (quarterly reports), and 8-K (current reports for material events) are primary legal disclosures for financial performance, risk factors, and corporate actions. These filings list exact figures for shares outstanding, revenue, and other metrics.
Earnings releases and investor presentations: Exelixis publishes quarterly earnings releases and investor presentations on its investor relations website, which provide summarized results, guidance, and pipeline updates.
Historical price lookup and stock quote: The company’s IR site and major financial portals provide downloadable historical price data and current quotes for exelixis stock.

As of 2026-01-27, investors should check Exelixis Investor Relations for the most recent 10-Q/10-K and for press release dates. The precise numerical data (e.g., quarterly revenue, EPS, and share counts) should be retrieved directly from these primary sources to ensure accuracy and date-stamped verification.

References and external links

Primary sources to verify figures and statements in this guide include:

Exelixis Investor Relations (press releases, financial reports, historical price lookup, and investor presentations). As of 2026-01-27, the IR site is the authoritative source for company disclosures.
SEC filings (10-K, 10-Q, 8-K) which provide audited financials and material event reporting.
Major financial-data portals and market-data providers (for real-time price, market cap, average volume, beta, analyst coverage summaries and price-targets), which update market metrics daily.

As always, consult primary filings and official corporate disclosures first for verifiable, date-stamped numbers. This guide is designed to help you find and interpret those sources; it does not replace primary documents or professional advice.

Further exploration and next steps

If you want to monitor exelixis stock more closely:

Check Exelixis’s IR page for the latest press releases and SEC filings to confirm numeric values and event dates.
Use a reputable charting service to watch intraday volume and option flow around earnings and trial readouts.
Consider using Bitget to view quotes and execute trades for exelixis stock where available; for Web3 wallet integration or custody of digital assets related to your broader portfolio, explore Bitget Wallet.

This guide is informational and neutral in tone. It summarizes public information and points you to primary sources for up-to-date, verifiable data about exelixis stock.

Note on reporting dates and sources: As of 2026-01-27, this guide references Exelixis Investor Relations, SEC filings, and leading financial-data providers for summarized metrics and historical context. For any specific numerical value (market capitalization, average daily volume, 52-week range, and analyst price targets), please consult the date-stamped company filings and market-data pages to confirm the latest figures.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.